TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04498260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local steroid - triamcinolone acetonide
Description: (triamcinolone acetonide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral steroid - predonisolone
Description: (predonisolone)
Study: NCT04582968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyrotinib Plus Capecitabine combined with brain radiotherapy
Description: Drug combined with radiation
Study: NCT04427618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Intravenous 1g TXA (500mg/5ml, given intermittent over approximately 10 minutes) given within approximately 10 minutes before skin incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision
Study: NCT04325191

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Daily consumption of a high sodium diet and melatonin for 10 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: aily consumption of a high sodium diet and placebo for 10 days
Study: NCT02616341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team ERP (T-ERP) Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Study: NCT02646579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal and Peripheral Dry Needling
Description: Participants will be positioned lying flat and the relevant spinal level will be treated using a Seirin L- type 50 mm needle. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Dry Needling
Description: Participants will be positioned lying flat and the relevant peripheral points will be treated using a Seirin L- type 50 mm needle. The peripheral treatment site(s) will be determined by the physical therapist's palpation of active or latent trigger points or tender points. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
Study: NCT03662477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: NK cells were generated in good manufacturing practice (GMP) condition. In brief, PBMCs were isolated from 50mL patient's blood with Ficoll-Hypaque(Morecell Biomedical Co. Ltd., Shenzhen, China). Then the Human NK Cell Culture Kit (Cat. No.~MCF-004, Morecell Biomedical Co. Ltd., Shenzhen, China) and Serum-free Medium for NK Cells (MCM-002, Morecell Biomedical Co. Ltd., Shenzhen, China) was used for induction of NK cells according to the manufacturer's instructions. Three days before NK cell transfusion, the NK cells were sampled and sent to detect the NK cell quality.
Study: NCT03800719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AWARD advice
Description: At baseline, brief smoking cessation advice following AWARD model will be delivered to subjects within about 2 to 5 minutes:~* Ask about smoking history and habit~* Warn about the risks of smoking using a leaflet~* Advise to quit smoking as soon as possible and use nicotine replacement therapy (NRT) or SC services~* Refer subjects to free smoking cessation services in Hong Kong if they agree~* Do it again: smokers who have tried to quit but relapsed will be encouraged to quit again and those who have reduced smoking will be advised to further reduce or quit smoking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: At baseline, brief smoking cessation advice following AWARD model will be delivered to subjects within about 2 to 5 minutes:~* Ask about smoking history and habit~* Warn about the risks of smoking using a leaflet~* Advise to quit smoking as soon as possible and use nicotine replacement therapy (NRT) or SC services~* Refer subjects to free smoking cessation services in Hong Kong if they agree~* Do it again: smokers who have tried to quit but relapsed will be encouraged to quit again and those who have reduced smoking will be advised to further reduce or quit smoking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health warning leaflet
Description: At baseline, an A5-sized leaflet will be given to subjects, which includes information about risks of smoking, pictures of smoking-related diseases, and smoking cessation services provided in Hong Kong.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health warning leaflet
Description: At baseline, an A5-sized leaflet will be given to subjects, which includes information about risks of smoking, pictures of smoking-related diseases, and smoking cessation services provided in Hong Kong.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active referral to smoking cessation (SC) services
Description: At baseline, subjects will be encouraged to seek smoking cessation services in Hong Kong. If subjects agree, their contact information will be sent to the preferred service providers for a quick appointment and follow-up.
Study: NCT01608321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham device
Description: Placebo Device that simulates active rTMS treatment
Study: NCT02757456

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aerobic Exercise program
Description: The 16-week program will consist of aerobic-type steady-state or interval exercises using a pedals attachable to the dialysis chairs. The purpose will be to slowly increase exercise duration by 5 minute increments to reach the goal of 30 min/treatment. The exercise program during hemodialysis sessions will contain a combination of aerobic and flexibility exercises, about 30 minutes of cycling with 10 minutes of warm up/stretching exercises and 10-15 minutes cool down. The frequency of exercise will be three sessions a week, during the first hour of dialysis treatment for the duration of 16 weeks. Blood pressure and heart continuous monitoring will be carried out during the exercise program. Exercise log sheets will be filled for each session for the 16 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No aerobic exercise is offered but baseline and end of study testing of the outcomes occur
Study: NCT03800719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active referral to smoking cessation (SC) services
Description: At baseline, subjects will be encouraged to seek smoking cessation services in Hong Kong. If subjects agree, their contact information will be sent to the preferred service providers for a quick appointment and follow-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular messages through Instant Messaging (IM)
Description: A total of pre-set 26 messages will be sent to subjects through WhatsApp 12 weeks after baseline to remind the quit date and to encourage abstinence. Messages are tailored based on subjects' sociodemographic characteristics and smoking habit following Social Cognitive Theory and Transtheoretical Model. Messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. The schedule will be adjusted according to the quit date and also smokers' requests. The format of regular messages will mainly be text-based but also include pictures, animations and videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support and referral to SC services through IM
Description: Personalized interactive text or voice conversation will be provided by trained smoking cessation advisors through WhatsApp for 3 months after baseline. Advisors will periodically proactively send messages to subjects to initiate the conversation (e.g. asking recent progress of smoking cessation) and deliver evidence-based advice. Advisors will also actively refer subjects, if they have expressed the need, to smoking cessation services providers. A standard operation algorithm for advisors used in the pilot feasibility trial will be modified for the use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Message on general health delivered by short message service (SMS)
Description: After baseline, regular messages using SMS will be sent to subjects with similar frequency to Intervention group. The messages include information on general health and reminders on follow-up surveys and biochemical validation for quitting.
Study: NCT04145570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib HCl 150 mg
Description: Concentrations of erlotinib were measured from the samples collected over a 72 hour interval after receiving either Erotinib generic or Tarceva original. Later, after 14 days, a crossover was took place with the same measures.~dosing in each period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tarceva®
Description: Tarceva® 150 mg
Study: NCT05330650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coated Vicryl+
Description: We used coated suture for : hystetrotomy reparation / aponeurosis and skin closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl
Description: We used non coated suture for : hystetrotomy reparation / aponeurosis and skin closure.
Study: NCT00002816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT03622372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative repair of Zone 2 FDP tendon lacerations
Description: Zone 2 tendon laceration(s) will be surgically repaired either using the experimental device or the active comparator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative repair of Zone 2 FDP tendon lacerations
Description: Zone 2 tendon laceration(s) will be surgically repaired either using the experimental device or the active comparator
Study: NCT04583072

Intervention type: DIAGNOSTIC_TEST
Intervention: The Stockholm3 test
Description: Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.

Intervention type: DIAGNOSTIC_TEST
Intervention: The Stockholm3 test
Description: Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.

Intervention type: DIAGNOSTIC_TEST
Intervention: The Stockholm3 test
Description: Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.

Intervention type: DIAGNOSTIC_TEST
Intervention: The Stockholm3 test
Description: Venipuncture: Prior to the biopsy the blood will be collected in 2 EDTA (lavender top) x 4 ml tubes will be removed after obtaining consent from the subjects.
Study: NCT01711736

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza GSK2282512A vaccine
Description: 1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: 1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
Study: NCT00478218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg administrated by PO (with food)on Days 1, 8, 15 \& 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 25 mg administrated by PO (with food)on Days 1-21
Study: NCT03333564

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3
Description: 50,000 IU VD3 / week for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega3-FA
Description: 300 mg of omega3-FA once daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3 and Omega-3FA
Description: 50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
Study: NCT04438317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pleural drainage procedure with Seldinger procedure
Description: Pleural drainage using Seldinger technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pleural drainage procedure with surgical-like technique
Description: Pleural drainage using Surgical-like technique.
Study: NCT00821496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol, norethindrone, VI-0521
Description: Oral contraceptive
Study: NCT01643382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Asp(B28)-
Description: Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
Study: NCT05026359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral ankle coordination training
Description: Developed a novel bilateral ankle coordination training program with visual feedback and bilateral ankle control, based on the concept of bilateral movement therapy. The bilateral ankle coordination training includes 3 days a week, 30 minutes each time, lasting 4 weeks, and a total of 12 training sessions.
Study: NCT03994666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic umbilical cord-derived mesenchymal stem cells
Description: Injection of mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic umbilical cord-derived mesenchymal stem cells
Description: Injection of mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl)
Description: Placebo injection
Study: NCT02426736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Performed with real time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Performed with real time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Performed with real time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Performed with real time ultrasound guidance.
Study: NCT03360643

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-care ultrasound prior to radiology ultrasound
Description: Point-of-care ultrasound performed by pediatric emergency medicine physicians prior to radiology-performed ultrasound

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Radiology-performed ultrasound
Description: Ultrasound performed an ultrasound technician and/or radiologist, and interpreted by a radiologist
Study: NCT03948334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL389 30mg
Description: 30mg of ZPL389; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL389 50mg
Description: 50mg of ZPL389; once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCS and/or TCI
Description: Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCS and/or TCI
Description: Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.
Study: NCT04617067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol 12mcg, administered orally on every day of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) and Nab-paclitaxel
Description: GEM (at 1,000 mg/m2) and Nab-paclitaxel (at 125 mg/m2 of bodysurface area), administered weekly for 3 of every 4 weeks (on days 1, 8 and 15 only).
Study: NCT03197584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 acid ethyl esters
Description: omega-3 acid ethyl esters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Stereotactic Body Radiation Therapy (SBRT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist IL-15 complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-HER2 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-MUC1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Heat-killed S. cerevisiae yeast expressing the mutated RAS oncoproteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK®
Description: NK-92 \[CD16.158V, ER IL-2\]
Study: NCT05058222

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Breathing Exercise after every 3hrs, each session consists of 10 deep breaths Exercise
Description: • The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Breathing Exercise after every 3hrs, each session consist of 30 deep breaths Exercise
Description: • The intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days).
Study: NCT00298974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone / acetaminophen extended release
Description: 2 tablets twice daily
Study: NCT03622372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoNextions TR Implant System
Description: The CoNextions TR Implant System will be used to repair Zone 2 FDP tendon laceration(s).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4-strand locked cruciate repair
Description: A 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture will be used to repair Zone 2 FDP tendon laceration(s).
Study: NCT03733756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM preserving longitudinal muscle
Description: participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: POEM involving longitudinal muscle
Description: participants are operated POEM involving both circular and longitudinal muscle
Study: NCT00298974

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets twice daily
Study: NCT01907464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical parameters description
Description: description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical parameters description
Description: description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms